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Abstract 
The anorectic and dipsogenic effects of the pancreatic hormone amylin are mediated by the 
area postrema and the subfornical organ. We tested the effectiveness of a new amylin 
antagonist, a so-called RNA Spiegelmer, by electrophysiological in vitro recordings from the 
rat subfornical organ and by immunohistological c-Fos studies in the area postrema. Amylin`s 
excitatory effect on subfornical organ neurons was blocked by the anti-amylin Spiegelmer. 
Peripheral administration 5 h prior to amylin also suppressed the amylin-induced activation 
(c-Fos expression) in the area postrema. The biostable anti-amylin Spiegelmer may be 
therapeutically beneficial in conditions associated with high plasma amylin levels, such as 
cancer anorexia occurring during certain pancreatic tumors. 
 
Key words: amylin, Spiegelmer, NOX-A42, area postrema, subfornical organ, 
electrophysiology, immunohistochemistry 
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Introduction 
Amylin is a 37-amino acid peptide, co-secreted with insulin from pancreatic ß-cells in 
response to food intake [1]. Exogenous amylin potently reduces food intake [2, 3], gastric 
emptying and glucagon secretion [4, 5]. Peripheral amylin’s anorectic action seems to be 
mediated by the area postrema [6, 7], a circumventricular organ lacking a functional blood-
brain-barrier [8]. In addition to its anorectic effect, amylin may also contribute to prandial 
drinking most likely via an action on angiotensin II sensitive neurons of the subfornical organ 
[9]. The subfornical organ also belongs to the circumventricular organs and, similar to the 
area postrema, expresses a high density of amylin binding sites [10, 11, 12]. As a member of 
the calcitonin family, amylin binds to calcitonin receptors that exhibit an affinity for amylin 
when co-expressed with receptor activity modifying protein (RAMP) 1 or 3 [13, 14]. 
In previous electrophysiological and immunohistological studies we characterized the effects 
of amylin on neuronal activity in the area postrema [15, 16] and the subfornical organ [9, 17]. 
In both structures, amylin induces dose-dependent excitatory effects that are blocked by the 
peptidergic amylin antagonist AC187. AC187, a truncated analogue of salmon calcitonin [18], 
reduces the excitatory effect of amylin on area postrema and subfornical organ neurons [9, 
16], the amylin-induced c-Fos expression in the area postrema [15] and attenuates peripheral 
amylin’s anorectic effect when infused directly into the area postrema [7]. Recently, a new 
class of hormone antagonists has been developed, the so-called Spiegelmers (German: Spiegel 
= mirror). Spiegelmers are mirror image L-oligonucleotides with high affinity towards a given 
target molecule, leading to a blockade of its biological activity [see ref. [19] for review]. Due 
to their L-ribose containing sugar-phosphate backbone, Spiegelmers are highly resistant to 
nuclease degradation and remain stable for more than sixty hours in biological fluids such as 
human plasma [19]. In addition to their usefulness as experimental tools, they may also be 
used as therapeutic agents. It has already been demonstrated that the anti-ghrelin SPM NOX-
B11 when infused into the tail vein, suppresses ghrelin-induced food intake and c-Fos 
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induction in the arcuate nucleus in rats [20]. Together with the observation that chronic NOX-
B11 administration lowers body weight [20, 21], it may be beneficial for the treatment of 
obesity.  
The aim of the present study was to provide functional in vitro and in vivo evidence that a 
newly developed anti-amylin Spiegelmer antagonizes the effects of amylin on area postrema 
and subfornical organ neurons. We used two different approaches. (1) In electrophysiological 
single cell recordings obtained from slice preparations, we investigated the ability of the anti-
amylin Spiegelmer to block the excitatory action of amylin on subfornical organ neurons in 
vitro. (2) In immunohistological studies we determined whether the anti-amylin Spiegelmer 
blocks the amylin-induced c-Fos expression in the area postrema under in vivo conditions. 
 
 
Methods 
The anti-amylin Spiegelmer used in this study is a 42 nucleotide L-RNA with the sequence 
5’-GGACUGAUGGCGCGGUCCUAUUACGCCGAUAGGGUGAGGGGA-3’. The 
molecule is a variant of the previously published Spiegelmer STAR-F12Δ43-48, whereby the 
adenosines at positions 30 and 35 were substituted to uridines [22]. The biologically inactive 
control Spiegelmer has the arbitrary sequence 
5’-UAAGGAAACUCGGUCUGAUGCGGUAGCGCUGUGCAGAGCU-3’. The Spiegelmer 
used in the in vivo studies (NOX-A42) was modified with a 40 kD polyethylene glycol (PEG) 
moiety to reduce renal excretion [21]. All Spiegelmers were synthesized at NOXXON Pharma 
AG.  
 
Male adult Wistar rats (200-300 g) were used for all experiments. Rats had ad libitum access 
to standard laboratory rat chow (890 25 W16, Provimi Kliba, Gossau, Switzerland) and water, 
unless stated otherwise. The animals were maintained in a temperature-controlled room on an 
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artificial 12:12-h dark-light cycle (21 ± 1°C, lights on at 3:00 AM) and adapted to the housing 
conditions and handling for at least 2 weeks before the start of the experiments. 
The slice preparation of the subfornical and the electrophysiological recording technique were 
identical to the procedures described previously [9, 17]. Briefly, extracellular recordings of 
action potentials from spontaneously active subfornical organ neurons were obtained using 
glass coated platinum-iridium electrodes. After recording the baseline activity of a single 
neuron for at least 5 min, stimulations were conducted by switching to a superfusion solution 
(10 ml) containing the investigated drugs. The following stimuli were applied: 1. rat amylin 
(10-7 M, Bachem AG, Bubendorf, Switzerland), 2. rat amylin (10-7 M) plus anti-amylin 
Spiegelmer (50 x 10-7 M) and 3. rat amylin plus inactive Spiegelmer (50 x 10-7M). The 
Spiegelmers were dissolved in distilled water and were pre-incubated with amylin for 15 min 
at room temperature before the start of the superfusion. When amylin was applied alone the 
amylin solution was kept under the same conditions. To exclude that the Spiegelmers cause 
any changes in the discharge rate, control superfusions of these substances (50 x 10-7 M) were 
applied without amylin. Action potential recordings were analysed using the software Spike2 
(Cambridge Electronic Design, England). From the continuously recorded rate meter counts, 
the average discharge rate of each neuron was evaluated for 60 seconds prior to the stimulus. 
This value (spontaneous discharge rate) was used to normalize changes in firing rate, 
expressed as % change of the spontaneous discharge rate. If the averaged change of discharge 
rate during the amylin response was larger than ± 20% and ± 0.5 spikes/s, the neuron was 
considered amylin sensitive. In addition to the mean change of the discharge rate during the 
entire responses, the peak values of the responses were calculated on a basis of a 30 s interval 
during which the firing rate was maximal. Finally, the duration between the application of the 
drugs and the onset of effect (latency) and the duration of the entire responses were 
determined. The parameters of the electrophysiological responses were expressed as means ± 
standard errors (M ± SEM).  
 8
For the immunohistological c-Fos studies four groups rats (200-230 g) were used (n=5 per 
group). All animals were food deprived for 26 h beginning at dark onset. After 19 h of fasting, 
i.e. 5h before subsequent dark onset, two groups were pre-treated with NOX-A42 (3mg/kg i.v. 
into the tail vein), while the two other groups received control infusions of saline. Ten 
minutes before dark onset, one Spiegelmer and one saline treated group were injected with 
amylin (20 μg/kg s.c.), while the two remaining groups received saline. Two hours after these 
treatments, rats were deeply anaesthetized (pentobarbital 100 mg/kg, i.p.) and transcardially 
perfused with ice-cold sodium phosphate-buffered saline (PBS, 0.1 M, pH 7.4), followed by 
4% paraformaldehyde in 0.1 M PBS. The immunohistological c-Fos staining was identical to 
the method described previously [23].  
In the electrophysiological studies statistical differences between the responses were 
evaluated by Friedman Repeated Measures ANOVA on Ranks followed by Student-Newman-
Keuls method for multiple pairwise comparison. For quantification of the c-Fos responses, c-
Fos immunoreactive (c-Fos-IR) cells were counted for each animal from xx slices of the area 
postrema (according to the brain map of Paxinos and Watson [24]). All slices from each 
animal were taken from corresponding rostrocaudal levels in order to exclude quantitative 
differences due to variations in the cross sectional area. The data are expressed as average 
number of cells/section ± SEM. Differences between the groups were evaluated by one way 
ANOVA and the least significant difference pairwise multiple comparison test. For all 
statistical tests P< 0.05 was considered significant. 
 
 
 
 
 
 
 9
Results 
Only amylin sensitive subfornical organ neurons were included in the electrophysiological 
analysis to test for the blocking capacity of the anti-amylin SPM. In total, six amylin 
responsive cells have been successfully tested with all three stimuli (amylin, amylin/anti-
amylin Spiegelmer and amylin/inactive Spiegelmer). In contrast to the inactive Spiegelmer, 
the anti-amylin Spiegelmer effectively blocked the amylin-mediated excitations in the 
subfornical organ. Figure 1a illustrates a typical recording of an amylin-sensitive subfornical 
organ neuron demonstrating the blockade of amylin’s excitatory action when co-applied with 
anti-amylin Spiegelmer, while the inactive Spiegelmer did not affect the amylin-induced 
response. The average excitatory effect of amylin calculated from the mean increases in firing 
rates of all tested neurons was significantly higher than the averaged response observed after a 
co-application of amylin and the active Spiegelmer. The mean excitatory response after 
application of amylin plus inactive Spiegelmer was similar to that of amylin alone. Table 1 
summarizes all mean effect parameters for the different stimuli. Neither the active SPM (n=3) 
nor the inactive SPM (n= 3) affected neuronal activity when superfused alone (Fig. 1b). 
In experimentally independent in vivo studies we confirmed the amylin antagonistic action of 
the Spiegelmer NOX-A42, which significantly attenuated the amylin-induced activation of 
AP neurons as detected by c-Fos expression. Almost no activated neurons were observed in 
saline/saline treated animals and in NOX-A42/saline treated rats (Fig. 2). While saline/amylin 
treatment lead to abundant c-Fos positive nuclei, significantly fewer cells were detected in 
NOX-A42/amylin injected animals. In the Spiegelmer pretreated group the amylin-induced c-
Fos response in the AP was decreased by 54 % relative to the saline/amylin injected animals 
(Fig. 3).  
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Fig. 1. a) Continous rate meter recording of a spontaneously active neuron from the rat subfronical 
organ. The amylin-induced excitation was antagonized by co-application of the anti-amylin 
Spiegelmer, while the biologically inactive Spiegelmer did not affect the amylin-mediated excitation. 
b) Continous rate meter recording of a spontaneously active neuron from the rat subfronical organ. 
Neither the inactive SPM nor the anti-amylin Spiegelmer affected neuronal activity when superfused 
alone.  
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Table 1. Effect parameters of the electrophysiological responses of rat subfornical neurons  
Effect parameter  amylin amylin +  inactive Spiegelmer
 amylin +  
anti-amylin 
Spiegelmer 
Mean latency [s] 74.5 ± 23.6 a 84.3 ± 28.9 a 36.3 ± 11.3 a 
Mean response [%] 45.4 ± 5.8 a 44.8 ± 11.9 a 4.8 ± 3.9 b 
Mean response [spikes/s] 3.4 ± 0.4 a 3.4 ± 0.6 a 0.4 ± 0.2 b 
Peak response [spikes/s] 4.7 ± 0.4 a 4.7 ± 1.0 a 0.8 ± 0.3 b 
Mean response duration 
[s] 1142.5 ± 211.5 
a 1171.2 ± 220.5 a 381.2 ± 37.6 b 
 
 
Parameters are given for the responses induced by amylin (10-7 M) when superfused alone and in 
combination with inactive Spiegelmer or the anti-amylin Spiegelmer (both 50 x 10-7M). Anti-amylin 
Spiegelmer significantly blocked the amylin-induced excitatory response compared to superfusion of 
amylin alone or in combination with the inactive Spiegelmer. Different letters indicate significant 
differences (p<0.05). Values are means ± SEM (n=6). 
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Fig. 2. Immunohistochemical stainings of 20 µm thick coronal sections of the area postrema processed 
for c-Fos after injections of saline/saline (control), NOX-A42/saline, saline/amylin and NOX-
A42/amylin treated animals. NOX-A42 (3 mg/kg i.v.) reduced the amylin (20 µg/kg s.c.) induced c-
Fos expression in the area postrema.  
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Fig. 3. Quantification of c-Fos-immunoreactive (c-Fos-IR) nuclei in the area postrema of the different 
experimental groups. Bars represent group means (± SEM). Amylin (20 µg/kg s.c.) elicited a 
significant increase of c-Fos expression while anti-amylin Spiegelmer NOX-A42 alone had no effect 
on area postrema neurons. The pre-treatment with NOX-A42 (3 mg/kg i.v.) led to a significant 
attenuation of the amylin induced c-Fos expression. Bars with different letters are significantly 
different (P < 0.05). 
 
Discussion 
In line with previous studies [9, 15] amylin significantly stimulated subfornical organ and 
area postrema neurons which are considered the main target structures for circulating amylin. 
As shown by electrophysiological recordings, co-application of the inactive Spiegelmer did 
not affect amylin`s excitatory responses on subfornical organ neurons. The reason why the 
latency of the amylin-mediated excitation was not longer under the blockade of amylin, as it 
may be expected, is unknown. In fact, there rather appeared to be a tendency for a shorter 
onset, which, however, was not significant. Neither the active nor the inactive control 
Spiegelmer seemed to produce any toxic or unspecific side effects when superfused alone.  
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Various amylin receptor antagonists had been useful in identifying amylinergic responses. 
AC187 is one of the most potent amylin receptor blockers [18]. In the present study we 
introduced a member of a new class of L-RNA-based hormone antagonists, the anti-amylin 
Spiegelmer NOX-A42. In contrast to classic hormone antagonists, Spiegelmers do not interact 
with the hormone receptor but reduce hormone action by a direct binding and thus reduce the 
biologically active free circulating hormone. As Spiegelmers are L-RNA compounds, they are 
not targets for nucleases that metabolize D-oligonucleotides [19]. This leads to a tremendous 
stability of Spiegelmers in biological fluids [19]. Therefore, Spiegelmers are useful 
antagonists for experimental purposes. The biostable anti-amylin Spiegelmer NOX-A42 could 
be a promising new tool to chronically block endogenous amylin action without using 
laborious and more invasive techniques like osmotic minipumps for chronic AC187 infusion. 
Under certain pathophysiological conditions, excessive amylin release may contribute to 
disorders in energy homeostasis, e.g. cancer anorexia occuring during certain pancreatic 
neoplastic diseases that are associated with chronically supraphysiological plasma amylin 
levels [25]. Amylin inhibition through NOX-A42 could be a promising new approach for the 
treatment of such disorders. 
 
Conclusion 
In summary, the present study provides in vitro and in vivo evidence that the anti-amylin SPM 
antagonizes amylinergic responses on neuronal function in the brain. Long acting anti-amylin 
SPMs may be useful as experimental tools but also as possible therapeutic compounds for 
disorders characterized by hyperamylinemia. 
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